Through CRISPR activation screens, we discovered that metabolite-sensing receptors can be used to mobilize natural killer cells and T cells toward solid tumors. Aberrant tumor metabolism is routinely used for diagnosis.
Our work now shows that tumor metabolism can be leveraged for therapeutics through the design of tumor-targeted metabolite-sensing effector immune cells. Access to this article via Institution of Civil Engineers Library is not available.
Benthani, F., Upadhaya, S. & Zhou, A.
Cancer cell therapies: global clinical trial trends and emerging directions. Nat.
Rev. Drug Discov.
24 , 898–899 (2025). A review that presents trends in cancer cell therapy clinical trials.
Pacesa, M., Pelea, O. & Jinek, M.
Past, present, and future of CRISPR genome editing technologies. Cell 187 , 1076–1100 (2024).
A review that presents CRISPR-based genetic tools. Hannedouche, S.
et al. Oxysterols direct immune cell migration via EBI2.
Nature 475 , 524–527 (2011). This paper reports oxysterols as the ligands of GPR183.
Zhu, A., Lee, D. & Shim, H.
Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin.
Oncol. 38 , 55–69 (2011).
Nature Immunology published a clinical update in Infectious Disease on 03 Apr 2026.
The item focuses on Engineering metabolite-sensing NK and T cells to target solid tumors.
Review the original article for the full source wording and details.